A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis
Status:
Completed
Trial end date:
2020-12-17
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled Phase 2A study to evaluate safety,
efficacy, PK, and dose response of oral CIN-102 in adults with idiopathic and diabetic
gastroparesis. The study will assess three oral doses of CIN-102 versus placebo in three
separate cohorts.